Next-generation sequencing has changed the face of cancer immunotherapy research by making tumor-specific cancer vaccines a reality. Whole exome sequencing and RNA sequencing combined with bioinformatic pipelines allow the prediction of neoantigen targets for cancer vaccines. In this review, we discuss the preclinical and early clinical evidence for cancer vaccines; describe methods and challenges in neoantigen prediction; and summarize emerging new technologies that will improve neoantigen cancer vaccine development.
Get full access to this article
View all access options for this article.
References
1.
AlvesJM, PosadaD (2018). Sensitivity to sequencing depth in single-cell cancer genomics. Genome Med, 10:29.
2.
AurisicchioL, PalloccaM, CilibertoG, PalomboF (2018). The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res, 37:86.
3.
BaisP, NamburiS, GattiDM, et al. (2017). CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. Bioinformatics, 33:3110-3112.
4.
Bassani-SternbergM (2018). Mass spectrometry based immunopeptidomics for the discovery of cancer neoantigens. Methods Mol Biol, 1719:209-221.
5.
Bassani-SternbergM, CoukosG (2016). Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr Opin Immunol, 41:9-17.
6.
BoegelS, LowerM, SchaferM, et al. (2012). HLA typing from RNA-Seq sequence reads. Genome Med, 4:102.
ButtsC, SocinskiMA, MitchellPL, et al. (2014). Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol, 15:59-68.
9.
CastleJC, KreiterS, DiekmannJ, et al. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res, 72:1081-1091.
10.
CibulskisK, LawrenceMS, CarterSL, et al. (2013). Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol, 31:213-219.
11.
DingL, WendlMC, McMichaelJF, RaphaelBJ (2014). Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet, 15:556-570.
12.
DvingeH, BradleyRK (2015). Widespread intron retention diversifies most cancer transcriptomes. Genome Med, 7:45.
13.
EditorialNB (2017). The problem with neoantigen prediction. Nat Biotechnol, 35:97.
14.
GriffithM, GriffithOL, SmithSM, et al. (2015). Genome modeling system: a knowledge management platform for genomics. PLoS Comput Biol, 11:e1004274.
HundalJ, CarrenoBM, PettiAA, et al. (2016). pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med, 8:11.
17.
KahlesA, LehmannKV, ToussaintNC, et al. (2018). Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell, 34:211-224 e216.
18.
KaumayaPT, FoyKC (2012). Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol, 8:961-987.
19.
KimS, KimHS, KimE, et al. (2018). Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. Ann Oncol, 29:1030-1036.
20.
KoboldtDC, ZhangQ, LarsonDE, et al. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res, 22:568-576.
21.
KreiterS, VormehrM, van de RoemerN, et al. (2015). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 520:692-696.
22.
KudrinA (2012). Overview of cancer vaccines: considerations for development. Hum Vaccin Immunother, 8:1335-1353.
23.
LiL, GoedegebuureSP, GillandersWE (2017). Preclinical and clinical development of neoantigen vaccines. Ann Oncol, 28(suppl_12):xii11-xii17.
24.
LiR, YuC, LiY, et al. (2009). SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics, 25:1966-1967.
25.
LiuC, YangX, DuffyB, et al. (2013). ATHLATES: accurate typing of human leukocyte antigen through exome sequencing. Nucleic Acids Res, 41:e142.
26.
LundegaardC, LamberthK, HarndahlM, et al. (2008). NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res, 36(Web Server issue):W509-512.
27.
McKennaA, HannaM, BanksE, et al. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 20:1297-1303.
28.
McLarenW, PritchardB, RiosD, et al. (2010). Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics, 26:2069-2070.
29.
MeleroI, GaudernackG, GerritsenW, et al. (2014). Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol, 11:509-524.
30.
MorseMA, ChuiS, HobeikaA, et al. (2005). Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol, 2:108-113.
31.
NavinNE (2014). Cancer genomics: one cell at a time. Genome Biol, 15:452.
32.
NielsenM, AndreattaM (2016). NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med, 8:33.
33.
OttPA, HuZ, KeskinDN, et al. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547:217-221.
34.
RobertC, SchachterJ, LongGV, et al. (2015). Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med, 372:2521-2532.
35.
SahinU, DerhovanessianE, MillerM, et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 547:222-226.
36.
SchubertB, WalzerM, BrachvogelHP, et al. (2016). FRED 2: an immunoinformatics framework for Python. Bioinformatics, 32:2044-2046.
37.
SeilerM, PengS, AgrawalAA, et al. (2018). Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep, 23:282-296 e284.
38.
ShiraishiY, SatoY, ChibaK, et al. (2013). An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res, 41:e89.
39.
ShuklaSA, RooneyMS, RajasagiM, et al. (2015). Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol, 33:1152-1158.
40.
SmartAC, MargolisCA, PimentelH, et al. (2018). Intron retention is a source of neoepitopes in cancer. Nat Biotechnol, 36:1056-1058.
41.
SonnhammerEL, von HeijneG, KroghA (1998). A hidden Markov model for predicting transmembrane helices in protein sequences. Proc Int Conf Intell Syst Mol Biol, 6:175-182.
42.
StoeckiusM, HafemeisterC, StephensonW, et al. (2017). Simultaneous epitope and transcriptome measurement in single cells. Nat Methods, 14:865-868.
43.
StronenE, ToebesM, KeldermanS, et al. (2016). Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science, 352:1337-1341.
44.
SzolekA, SchubertB, MohrC, et al. (2014). OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics, 30:3310-3316.
45.
TangSM, Subha (2017). neoantigenR: an annotation based pipeline for tumor neoantigen identification from sequencing data. bioRxiv; doi.org/10.1101/171843.
46.
TappeinerE, FinotelloF, CharoentongP, et al. (2017). TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics, 33:3140-3141.
47.
VansteenkisteJ, ZielinskiM, LinderL, et al. (2013). Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol, 31:2396-2403.
48.
WarrenRL, ChoeG, FreemanDJ, et al. (2012). Derivation of HLA types from shotgun sequence datasets. Genome Med, 4:95.
49.
WhitesideTL, DemariaS, Rodriguez-RuizME, et al. (2016). Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res, 22:1845-1855.
50.
ZhangJ, MardisER, MaherCA (2017). INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery. Bioinformatics, 33:555-557.
51.
ZhangJ, WhiteNM, SchmidtHK, et al. (2016). INTEGRATE: gene fusion discovery using whole genome and transcriptome data. Genome Res, 26:108-118.
52.
ZhangX, KimS, HundalJ, et al. (2017). Breast cancer neoantigens can induce CD8(+) T-cell responses and antitumor immunity. Cancer Immunol Res, 5:516-523.
53.
ZhouZ, LyuX, WuJ, et al. (2017). TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. R Soc Open Sci, 4:170050.
